Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group. von Minckwitz G, et al. Among authors: skacel t. Ann Oncol. 2008 Feb;19(2):292-8. doi: 10.1093/annonc/mdm438. Epub 2007 Sep 9. Ann Oncol. 2008. PMID: 17846019 Free article. Clinical Trial.
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS. von Minckwitz G, et al. Among authors: skacel t. Eur J Cancer. 2009 Mar;45(4):608-17. doi: 10.1016/j.ejca.2008.11.021. Epub 2008 Dec 26. Eur J Cancer. 2009. PMID: 19110415 Review.
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G. Loibl S, et al. Among authors: skacel t. BMC Cancer. 2011 Apr 12;11:131. doi: 10.1186/1471-2407-11-131. BMC Cancer. 2011. PMID: 21486442 Free PMC article. Clinical Trial.
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
Wildiers H, Dirix L, Neven P, Prové A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R. Wildiers H, et al. Among authors: skacel t. Breast Cancer Res Treat. 2009 Mar;114(1):103-12. doi: 10.1007/s10549-008-9970-z. Epub 2008 Mar 16. Breast Cancer Res Treat. 2009. PMID: 18344024 Clinical Trial.
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N. Russell N, et al. Among authors: skacel t. Haematologica. 2008 Mar;93(3):405-12. doi: 10.3324/haematol.11287. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268285 Free article. Clinical Trial.
30 results